ArticleThe EMBO journal2007
Antibody evasion by the N terminus of murid herpesvirus-4 glycoprotein B.
Article in The EMBO journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Multivalent binding of herpesvirus to living cells is tightly regulated during infection.Science advances · 2018Article
- Bovine Herpesvirus 4 Modulates Its β-1,6-N-Acetylglucosaminyltransferase Activity through Alternative Splicing.Journal of virology · 2016Article
- Deletion of Murid Herpesvirus 4 ORF63 Affects the Trafficking of Incoming Capsids toward the Nucleus.Journal of virology · 2015Article
- Illumination of murine gammaherpesvirus-68 cycle reveals a sexual transmission route from females to males in laboratory mice.PLoS pathogens · 2013Article
- Proteomic characterization of bovine herpesvirus 4 extracellular virions.Journal of virology · 2012Article
- Myeloid infection links epithelial and B cell tropisms of Murid Herpesvirus-4.PLoS pathogens · 2012Article
- Bovine herpesvirus type 4 glycoprotein L is nonessential for infectivity but triggers virion endocytosis during entry.Journal of virology · 2012Article
- Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies.PLoS pathogens · 2012Article
- Antibody evasion by a gammaherpesvirus O-glycan shield.PLoS pathogens · 2011Article
- A mechanistic basis for potent, glycoprotein B-directed gammaherpesvirus neutralization.The Journal of general virology · 2011Article
- The bovine herpesvirus 4 Bo10 gene encodes a nonessential viral envelope protein that regulates viral tropism through both positive and negative effects.Journal of virology · 2011Article
- Vaccination with murid herpesvirus-4 glycoprotein B reduces viral lytic replication but does not induce detectable virion neutralization.The Journal of general virology · 2010Article
- Antibody limits in vivo murid herpesvirus-4 replication by IgG Fc receptor-dependent functions.The Journal of general virology · 2009Article
- Glycoprotein L sets the neutralization profile of murid herpesvirus 4.The Journal of general virology · 2009Article
- In vivo importance of heparan sulfate-binding glycoproteins for murid herpesvirus-4 infection.The Journal of general virology · 2009Article
- Article
- Glycoprotein B switches conformation during murid herpesvirus 4 entry.The Journal of general virology · 2008Article
- The murid herpesvirus-4 gH/gL binds to glycosaminoglycans.PloS one · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Herpesviruses characteristically transmit infection from immune hosts. Although their success in escaping neutralization by pre-formed antibody is indisputable, the underlying molecular mechanisms remain largely unknown. Glycoprotein B (gB) is the most conserved component of the herpesvirus entry machinery and its N terminus (gB-NT) is a common neutralization target. We used murid herpesvirus-4 to determine how gB-NT contributes to the virus-antibody interaction. Deleting gB-NT had no obvious impact on virus replication, but paradoxically increased virion neutralization by immune sera. This reflected greater antibody access to neutralization epitopes on gH/gL, with which gB was associated. gB-NT itself was variably protected against antibody by O-linked glycans; on virions from epithelial cells it was protected almost completely. gB-NT therefore provides a protective and largely protected cover for a vulnerable part of gH/gL. The conservation of predicted glycosylation sites in other mammalian herpesvirus gB-NTs suggests that this evasion mechanism is widespread. Interestingly, the gB-NT glycans that blocked antibody binding could be targeted for neutralization instead by a lectin, suggesting a means of therapeutic counterattack.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.